LGVN Latest News, Press Relases and Analysis

All

Press Releases

21 days ago - By: Longeveron

Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

26 days ago - By: Longeveron

George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors

a month ago - By: Longeveron

Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa

2 months ago - By: Longeveron

Longeveron® Announces Key Leadership Updates

2 months ago - By: Longeveron

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

3 months ago - By: Benzinga

Preview: Longeveron's Earnings

3 months ago - By: Longeveron

Longeveron Announces Up To $17.5 Million Public Offering

6 months ago - By: Benzinga - Mentions: MSC ELUT ACIW JYNT ...

Earnings Scheduled For May 8, 2025

2 months ago - By: The Motley Fool

Longeveron Posts 32% Revenue Drop in Q2

2 months ago - By: Longeveron

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: Longeveron

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

3 months ago - By: Longeveron

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

3 months ago - By: Longeveron

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

4 months ago - By: Longeveron

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

4 months ago - By: Longeveron

Longeveron® Appoints Than Powell as Chief Business Officer

4 months ago - By: Longeveron

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

5 months ago - By: Longeveron

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

5 months ago - By: Longeveron

Longeveron® to Attend BIO International Convention 2025

6 months ago - By: Longeveron

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

6 months ago - By: Longeveron

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

6 months ago - By: Longeveron

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

6 months ago - By: Longeveron

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

6 months ago - By: Longeveron

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

6 months ago - By: Longeveron

Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025

7 months ago - By: Longeveron

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease

8 months ago - By: Longeveron

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease

8 months ago - By: Longeveron

Longeveron® to Present at the 37th Annual Roth Conference

8 months ago - By: Longeveron

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

8 months ago - By: Longeveron

Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025

8 months ago - By: Longeveron

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

8 months ago - By: Longeveron

LONGEVERON INC-A (LGVN) Stock News

LGVN Latest News, Press Relases and Analysis

Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors

Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa

Longeveron® Announces Key Leadership Updates

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Preview: Longeveron's Earnings

Longeveron Announces Up To $17.5 Million Public Offering

Earnings Scheduled For May 8, 2025

Longeveron Posts 32% Revenue Drop in Q2

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

Longeveron® Appoints Than Powell as Chief Business Officer

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Longeveron® to Attend BIO International Convention 2025

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease

Longeveron® to Present at the 37th Annual Roth Conference

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025